It's a single molecule that activates three receptors simultaneously: GLP-1 (like semaglutide), GIP (like tirzepatide), and glucagon (new)
Food and Drug Administration, Understanding Investigational Drugs , April 2, 2019 GoodRx, Retatrutide for Weight Loss: Availability, Dosage, and More , June 25, 2026 Food and Drug Administration, Expanded Access, accessed June 29, 2026 Eli Lilly, Expanded Access | Compassionate Use | Clinical Trials , accessed June 29, 2026 WBUR | Here & Now, An extraordinary new obesity drug is still awaiting FDA approval
The Medicare GLP-1 Bridge seeks to test whether providing access to GLP-1 products at a uniform, CMS-negotiated net price will help improve beneficiary outcomes and reduce long-term Medicare spending, Kelly Strachan, CMS health insurance specialist and Innovation Center fellow, said, according to The Hill
6 Likes AlexKChen March 5, 2025, 11:39am #68 Im going to finally stop holding off and inject mine tonight, Ive had too much disruption from late night hunger Apparently this one (Retatrutide) helps with lean mass retention relative to Semaglutide